The first results from the ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran) were released at the 2021 Pediatric Academic Societies virtual meeting and show highly promising results.
Alnylam Pharmaceuticals, Inc. announced positive preliminary results from the company's ILLUMINATE-A Phase 3 study of OXLUMO® (lumasiran), which is an RNAi therapeutic targeting hydroxyacid oxidase 1 – the gene encoding glycolate oxidase, to treat primary hyperoxaluria type 1, an ultra-rare genetic disease characterized by oxalate overproduction in the liver.1 The data were released at the Pediatric Academic Societies virtual meeting.
The trial was a 6 month, randomized, double-blind, placebo-controlled, global, multicenter Phase 3 study that studied efficacy and safety of lumasiran in 39 patients aged 6 years and older who had a documented diagnosis of primary hyperoxaluria type 1. Patients were randomized 2:1 to either receive 3 monthly doses of the drug or placebo followed by quarterly doses at 3 mg/kg. Twenty-four of the participants had valid renal ultrasounds at baseline and 11 had improvement in the nephrocalcinosis grade relative to baseline and 4 remained stable. Only 3 children experienced worsening in the grade. In the 14 children with baseline nephrocalcinosis and available ultrasounds, 11 showed improvement when compared to the baseline and 8 of those children saw improvement in both kidneys. Common adverse effects included injection site reaction, erythema, pain, pruritus, and swelling.
Alnylam Pharmaceuticals, Inc. indicated that further data would be available later in the year.
Reference
1. Alnylam Pharmaceuticals, Inc. Alnylam announces positive early results on clinical outcome measures from ILLUMINATE-A phase 3 study of OXLUMO® (lumasiran). Published May 3, 2021. Accessed May 3, 2021. https://www.businesswire.com/news/home/20210503005235/en/
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.